Expanded Access Program:Lenalidomide With or Without Dexamethasone In Previously Treated Subjects With Multiple Myeloma

Completed · Phase 3

Conditions studied: Multiple Myeloma

In brief

Subjects who qualify for participation will receive lenalidomide with or without dexamethasone in 4 week cycles until disease progression is documented or lenalidomide becomes commercially available for the indication of multiple myeloma.

Key facts

Study ID

NCT00179647

Run by

Celgene Corporation

People needed

1913

Starts

2005-09-01

Expected to finish

2009-04-01

Last updated by the study team

2010-03-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Must understand and voluntarily sign an informed consent form.
• Must be > or = to 18 years of age at the time of signing the informed consent form.
• Must be able to adhere to the study visit schedule and other protocol requirements.
• Must be diagnosed with multiple myeloma that is progressing after at least 2 cycles of anti-myeloma treatment or that has relapsed with progressive disease after treatment.
• Subjects may have been previously treated with thalidomide and/or radiation therapy. In addition, radiation therapy initiated prior to or at baseline (Day 1) may be given concurrently with study therapy, provided that all other eligibility criteria are satisfied.
• Measurable levels of myeloma paraprotein in serum (>/=0.5 g/dL) or urine (>/=0.2 g excreted in a 24-hour collection sample).
• Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.
• Women of childbearing potential (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug. In addition, sexually active WCBP must agree to use adequate contraceptive methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study medication.

You may not qualify if…

• Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
• Pregnant or lactating females.
• Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
• Any of the following laboratory abnormalities:
• Absolute neutrophil count (ANC) <1,000 cells/mm3 (1.0 x 109/L)
• Platelet count <75,000/mm3 (75 x 109/L) for subjects in whom <50% of the bone marrow nucleated cells are plasma cells.
• Platelet count <30,000/mm3 (30x109/L) for subjects in whom >/= 50% of bone marrow nucleated cells are plasma cells.
• Serum creatinine >2.5 mg/dL (221 mmol/L)
• Serum glutamic oxaloacetic transaminase (SGOT, aspartate transaminase [AST]) or serum glutamic pyruvic transaminase (SGPT, alanine transaminase [ALT]) >3.0 x upper limit of normal (ULN)
• Serum total bilirubin >2.0 mg/dL (34 mmol/L)
• Prior history of malignancies other than multiple myeloma (except for basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix or breast) unless the subject has been free of the disease for >/= 1 year.
• Known hypersensitivity to thalidomide or dexamethasone.
• Prior history of uncontrollable side effects to dexamethasone therapy.
• The development of a desquamating rash while taking thalidomide.
• Use of any standard/experimental anti-myeloma drug therapy within 28 days of the initiation of study drug treatment or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of the initiation of study drug treatment.

Where it is running

• Alta Bates Cancer Center — Berkeley, California, United States
• Scripps Cancer Center — La Jolla, California, United States
• Cedar Sinai Medical CenterDept of Medicine — Los Angeles, California, United States
• Kaiser Permanente Medical Group — San Diego, California, United States
• Stanford Cancer Center — Stanford, California, United States
• Kaiser Permanente Medical Center — Vallejo, California, United States
• University of ColoradoHealth Science Center — Aurora, Colorado, United States
• Rocky Mountain Cancer Center-Midtown — Denver, Colorado, United States
• Yale University School of Medicine — New Haven, Connecticut, United States
• Hematology Oncology, PC — Stamford, Connecticut, United States
• Delaware Clinical & Laboratory Physicians, PA — Newark, Delaware, United States
• University of Miami Medical School — Miami, Florida, United States
• Mount Sinai Comprehensive Cancer Center — Miami Beach, Florida, United States
• Gulf Coast Oncology — St. Petersburg, Florida, United States
• H Lee Moffitt Cancer Center — Tampa, Florida, United States
• The Palm Beach Cancer Institute — West Palm Beach, Florida, United States
• Emory University — Atlanta, Georgia, United States
• Northwestern University Med CtrDivision of Hem/Onc — Chicago, Illinois, United States
• Rush Cancer Institute — Chicago, Illinois, United States
• Indiana Univ Cancer Center Bone Marrow Transplantation Program Indiana Cancer Research Institute — Indianapolis, Indiana, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Wichita CCOP — Wichita, Kansas, United States
• Ochsner Clinic Foundation — New Orleans, Louisiana, United States
• University of Maryland Medical Center Greenbaum Cancer Ctr — Baltimore, Maryland, United States
• Mayo Clinic — Scottsdale, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.